Telehealth provider Tyto Care pulls in a total of $33.5M in series C

Tyto Care
Tyto Care's remote examination devices allow streamed, at-home checkups of the heart, lungs, skin, ears and throat. (Tyto Care)

Tyto Care, which makes telehealth equipment for at-home doctor’s exams, has raised an additional $9 million through an expansion of its 2018 series C round, bringing its total up to $33.5 million.

The funding round was led by Ping An Global Voyager Fund, with new money from Sanford Health, Itochu and Shenzhen Capital Group and its affiliates. The Israeli company plans to use the proceeds to help it expand into remote and rural communities in the U.S., Europe, Japan and China through strategic partnerships.

"Tyto Care's mission of making high-quality healthcare accessible from the comfort of home is crucial, especially in China,” said Zewang Ni, chairman of Shenzhen Capital Group. “We believe that telehealth will significantly improve the lives of Chinese consumers, whether they are parents with sick children at home, elderly patients facing chronic illnesses, or citizens living in remote areas with less access to medical care.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Tyto Care nets CE mark for digital, at-home doctor’s exams

Tyto previously raised $25 million in a January 2018 series B round to help grow U.S. sales of its FDA-approved digital stethoscope while working to enter the Chinese market. China’s Ping An led that round as well, with the support of Cambia Health Solutions, Walgreens, OrbiMed, Fosun Pharma and LionBird.

Tyto also recently paired up with Health Navigator, a digital health and telemedicine company, to integrate Health Navigator’s symptom checker into its platform.

The checker considers age, gender, pregnancy status, known medical problems and other clinical factors to generate a list of pre-diagnoses and recommendations for a specific symptom or problem, and acts as an assistant to guide patients through the use of digital health tools.

Tyto, meanwhile, offers hand-held, modular tools for examining the heart, lungs, skin, ears, throat, abdomen and body temperature, and beams the information remotely to a clinician. By extending the reach of specialists, the company believes it can cut readmission rates and recover revenue lost to emergency and urgent care centers.

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.